JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 2012 Nov; 12(9):1098-109.